Your browser doesn't support javascript.
loading
Efficacy of sacubitril and valsartan combined with bisoprolol in the treatment of chronic heart failure and its effect on N-terminal pro-brain natriuretic peptide level / 中国基层医药
Chinese Journal of Primary Medicine and Pharmacy ; (12): 1160-1164, 2023.
مقالة ي صينى | WPRIM | ID: wpr-991878
ABSTRACT

Objective:

To investigate the clinical efficacy of sacubitril and valsartan combined with bisoprolol in the treatment of chronic heart failure and its effect on N-terminal pro-brain natriuretic peptide (NT-pro BNP) level.

Methods:

The clinical data of 89 patients with chronic heart failure who received treatment in Jinan 2 nd People's Hospital from January 2020 to April 2022 were retrospectively analyzed. These patients were divided into Group A ( n = 48) and Group B ( n = 41) according to different treatment methods. Group A was treated with sacubitril and valsartan combined with bisoprolol. Group B was treated with sacubitril and valsartan combined with metoprolol. All patients were treated for 3 months. Clinical efficacy as well as heart function and NT-pro BNP level pre- and post-treatment were compared between the two groups. The incidence of adverse reactions was calculated in each group.

Results:

Total response rate in group A was significantly higher than that in group B [95.83% (46/48) vs. 82.93% (34/41), χ2 = 4.05, P < 0.05]. After treatment, the left ventricular ejection fraction in both groups increased significantly and the left ventricular ejection fraction in group A was significantly higher than that in group B ( t = 2.19, P < 0.05). After treatment, NT-pro BNP level in group A was (416.51 ± 30.56) ng/L, which was significantly lower than (450.20 ± 35.79) ng/L in group B ( t = 4.79, P < 0.001). There was no significant difference in the incidence of adverse reactions between the two groups ( P > 0.05).

Conclusion:

The efficacy of sacubitril and valsartan combined with bisoprolol in the treatment of chronic heart failure is superior to that of sacubitril and valsartan combined with metoprolol. The former can greatly decrease NT-pro BNP level. Corresponding drugs can be selected for the treatment of chronic heart failure according to the actual needs of patients.

النص الكامل: متاح الفهرس: WPRIM غرب المحيط الهادئ اللغة: صينى مجلة: Chinese Journal of Primary Medicine and Pharmacy السنة: 2023 نوع: مقالة

المراجع ذات الصلة

MEDLINE

...
LILACS

LIS

النص الكامل: متاح الفهرس: WPRIM غرب المحيط الهادئ اللغة: صينى مجلة: Chinese Journal of Primary Medicine and Pharmacy السنة: 2023 نوع: مقالة